InternationalUSRemember you can easily switch between MIP US and MIP International at any time

US News


International News


Magazine

Latest Issue March 2017


  • Roundtable: The second medical use challenge – full transcript

    Three leading patent specialists discussed one of the most challenging issues in IP at the moment – incentivising new uses for known drugs – at a recent roundtable discussion. The participants were: Jurgen Dressel, head of global patent litigation strategy, Novartis Pharma; Galit Gonen, VP and general counsel for Europe at Teva; and Professor Sir Robin Jacob, former Court of Appeal judge and professor at the Institute of Brand and Innovation Law, University College London

  • MIP Global Awards 2017: The highlights

    85 awards, including for corporate social responsibility and in-house achievement, were presented at Managing IP’s 12th Global Awards dinner at The Savoy in London last week. The photos from the event have also been published

  • Utynam’s Heirs

    Inspired by Valentine’s Day last month, Managing IP invited our Twitter followers to compose IP-related love poems, and received dozens of responses, from the beautiful to the bitter. Utynam has picked his favourites to share with you

  • Roundtable: The second medical use challenge – full transcript

    Three leading patent specialists discussed one of the most challenging issues in IP at the moment – incentivising new uses for known drugs – at a recent roundtable discussion. The participants were: Jurgen Dressel, head of global patent litigation strategy, Novartis Pharma; Galit Gonen, VP and general counsel for Europe at Teva; and Professor Sir Robin Jacob, former Court of Appeal judge and professor at the Institute of Brand and Innovation Law, University College London

  • Are you 3DP ready?

    3D printing is already causing disruption in some industries. Stella Wong considers how to develop a 3DP IP strategy, with a particular focus on the medical industry

  • Avoid the tax shock in licensing agreements

    Christopher M Neumeyer reviews the lessons to be learned from two recent cases where Taiwan companies were ordered to pay taxes on licensing fees paid to a foreign licensor

  • Trends to watch at the ITC after busy 2016 for IP investigations

    Highlights at the International Trade Commission in 2016 included the most Section 337 investigations since 2011, the first live hearing for a decade and the first antitrust claim for 25 years. Michael Loney asks ITC practitioners what trends they expect in 2017

  • A quiet year from the EU’s courts in design cases

    While 2016 was a quiet year for design decisions in the Court of Justice, 2017 looks to be a cracker year of important cases. In the first of two articles, David Stone looks back at the year that was. Next month, he looks forward to some of the key decisions expected in 2017

  • Keeping IP strategy alive

    Nick McDonald looks at the characteristics of an effective IP strategy and the dangers of failing to keep it alive in a business


profile

Managing IP

ManagingIP

ManagingIP profile

RT @mdloney: SCOTUS TC Heartland v Kraft Foods Group Brands oral argument transcript is up! https://t.co/v29vEKCILp

Mar 27 2017 07:50 ·  reply ·  retweet ·  favourite
ManagingIP profile

Likely to be an important question for some applicants, with UPC due to come into force in December this year https://t.co/ASuSYUpRqd

Mar 27 2017 04:40 ·  reply ·  retweet ·  favourite
ManagingIP profile

Don't forget to sign up for our next webinar, on IP in Asia, this Thursday at 3pm (London) https://t.co/gh3Ka8t9q1 @inoviaIP @Minesoftnews

Mar 27 2017 04:38 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


March 2017

Roundtable: The second medical use challenge – full transcript

Three leading patent specialists discussed one of the most challenging issues in IP at the moment – incentivising new uses for known drugs – at a recent roundtable discussion. The participants were: Jurgen Dressel, head of global patent litigation strategy, Novartis Pharma; Galit Gonen, VP and general counsel for Europe at Teva; and Professor Sir Robin Jacob, former Court of Appeal judge and professor at the Institute of Brand and Innovation Law, University College London



Most read articles

Supplements